IgM AL amyloidosis due to B cell lymphoproliferative disorder: Efficacy of high-dose melphalan followed by autologous stem cell transplantation

Amyloid

Volumn 11, Issue 2, 2004, Pages 130-135

  Gono, Takahisa ^a   Matsuda, Masayuki ^a   Shimojima, Yasuhiro ^a   Ishii, Wataru ^a   Yamamoto, Kanji ^a   Koyama, Jun ^a   Sakashita, Kazuo ^a   Koike, Kenichi ^a   Itoh, Susumu ^a   Isaka, Toshifumi ^b   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Matsuzaka Central Hospital   (Japan)

Author keywords

AL amyloidosis; Autologous peripheral blood stem cell transplantation; High dose melphalan; IgM; Lymphoplasmacytoid cell; Nephrotic syndrome

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; MELPHALAN; VINCRISTINE;

ADULT; AMYLOIDOSIS; ANAMNESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPY; FLOW CYTOMETRY; HEMATOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MALE; NEPHROTIC SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

AMYLOIDOSIS; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN M; LYMPHOPROLIFERATIVE DISORDERS; MALE; MELPHALAN; MIDDLE AGED; PLASMA CELLS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 20844434804     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.1080/13506120410001725994     Document Type: Article

References (19)

1. Kyle RA and Gertz MA (1995). Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 32, 45-59
2. Anagnostopoulos A and Giralt S (2002). Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM). Bone Marrow Transplant 29, 943-947
3. Gertz MA, Kyle RA and Noel P (1993). Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol 11, 914-920
4. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML, Escribano L, Barez A, Moro MJ, Hernandez J, Aguilera C, Cuello R, Garcia-Frade J, Lopez R, Portero J and Orfao A (2003). Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 30, 187-195
5. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA and Litzow MR (2000). Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26, 963-969
6. Fujihara S, Balow JE, Costa JC and Glenner GG (1980). Identification and classification of amyloid in formalin-fixed, paraffin-embedded tissue sections by the unlabeled immunoperoxidase method. Lab Invest 43, 358-365
7. Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, Koike K, Aizawa M and Ikeda S (2003). Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 42, 72-77
8. Matsuda M, Gono T, Shimojima Y, Hoshii Y and Ikeda S (2003). Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid: J Protein Folding Disord 10, 110-116
9. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR and Dimopoulos MA (2003). Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30, 110-115
10. Owen RG (2003). Developing diagnostic criteria in Waldenstrom's macroglobulinemia. Semin Oncol 30, 196-200
11. Pangalis GA, Kyrtsonis M-C, Kontopidou FN, Vassilakopoulos TP, Siakantaris MP, Dimopoulou MN, Kittas C and Angelopoulou MK (2003). Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Semin Oncol 30, 201-205
12. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF and Melton LJ 3rd (2003). Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102, 3759-3764
13. Zimmermann I, Gloor HJ and Ruttimann S (2001). General AL-amyloidosis: a rare complication in Waldenström's macroglobulinemia. Schweiz Rundsch Med Prax 90, 2050-2055
14. Gertz MA and Kyle RA (2003). Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 30, 325-328
15. Gertz MA, Anagnostopoulos A, Anderson K, Branagan AR, Coleman M, Frankel SR, Giralt S, Levine T, Munshi N, Pestronk A, Rajkumar V and Treon SP (2003). Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30, 121-126
16. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J and Anagnostopoulos N (2002). Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 20, 2327-2333
17. Desikan R, Dhodapkar M, Siegel D, Passas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Anaissie E, Barlogie B and Munshi NC (1999). High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinemia. Br J Haematol 105, 993-996
18. Yang L, Wen B, Li H, Yang M, Jin Y, Yang S and Tao J (1999). Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia. Bone Marrow Transplant 24, 929-930
19. Anagnostopoulos A, Aleman A and Giralt S (2003). Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions. Semin Oncol 30, 286-290